Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > See Sedi reports
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(296)
•••
Comment by inthnoon Oct 05, 2021 10:23am
201 Views
Post# 33966592

RE:See Sedi reports

RE:See Sedi reports
I do not quite understand the sedi as I am not that familiar but it would appear that maybe options were exercised and then sold but not sure.

Transaction ID Date of transaction
YYYY-MM-DD 		Date of filing
YYYY-MM-DD 		Ownership type (and registered holder, if applicable) Nature of transaction Number or value acquired or disposed of Unit price or exercise price Closing balance Insider's calculated balance Conversion
or exercise
price 		Date of expiry or maturity
YYYY-MM-DD 		Underlying security designation Equivalent number or value of underlying securities acquired or disposed of Closing balance of equivalent number or value of underlying securities  
Insider name: Brown, Deborah  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Common Shares  
        3812378 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights +3,496     48,948 48,948              
   
Security designation: Rights Restricted Share Units (Common Shares)  
        3812376 2021-10-01 2021-10-04 Direct Ownership : 54 - Exercise of warrants -8,134     0 0       Common Shares -8,134 0  
   
Insider name: Coffey, Matthew  
Insider's Relationship to Issuer: 4 - Director of Issuer, 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3781773 2021-07-27 2021-07-28 Direct Ownership : 52 - Expiration of options -1,894 40.9500   1,349,334 1,349,334       Common Shares -1,894 1,349,334  
   
Insider name: Holtham, Angela Frances  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Common Shares  
        3757992 2021-06-07 2021-06-07 Direct Ownership : 10 - Acquisition or disposition in the public market +7,000 3.5891   108,336 108,336              
   
        3812333 2021-09-30 2021-10-04 Direct Ownership : 57 - Exercise of rights +2,313     110,649 110,649              
   
        3812336 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights +8,134     118,783 118,783              
   
        3768779 2021-06-30 2021-06-30 Indirect Ownership :
Paul Holtham 		10 - Acquisition or disposition in the public market +2,313 3.4300   5,313 5,313              
   
Security designation: Rights Restricted Share Units (Common Shares)  
        3769079 2021-06-30 2021-06-30 Direct Ownership : 57 - Exercise of rights -2,313     13,589 13,589       Common Shares -2,313 13,589  
   
        3812330 2021-09-30 2021-10-04 Direct Ownership : 57 - Exercise of rights -2,313     11,276 11,276       Common Shares -2,313 11,276  
   
        3812335 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights -8,134     3,142 3,142       Common Shares -8,134 3,142  
   
Insider name: Pisano, Wayne  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Common Shares  
        3769096 2021-06-30 2021-06-30 Direct Ownership : 57 - Exercise of rights +5,033     169,937 169,937              
   
        3812343 2021-09-30 2021-10-04 Direct Ownership : 57 - Exercise of rights +5,033     174,970 174,970              
   
        3812345 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights +8,134     183,104 183,104              
   
Security designation: Rights Restricted Share Units (Common Shares)  
        3769089 2021-06-30 2021-06-30 Direct Ownership : 57 - Exercise of rights -5,033     20,004 20,004       Common Shares -5,033 20,004  
   
        3812340 2021-09-30 2021-10-04 Direct Ownership : 57 - Exercise of rights -5,033     14,971 14,971       Common Shares -5,033 14,971  
   
        3812344 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights -8,134     6,837 6,837       Common Shares -8,134 6,837  
   
Insider name: Seizinger, Bernd Robert  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Common Shares  
        3769083 2021-06-30 2021-06-30 Direct Ownership : 57 - Exercise of rights +6,101     242,341 242,341              
   
        3812365 2021-09-30 2021-10-04 Direct Ownership : 57 - Exercise of rights +6,101     248,442 248,442              
   
        3812369 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights +8,134     256,576 256,576              
   
Security designation: Rights Restricted Share Units (Common Shares)  
        3769082 2021-06-30 2021-06-30 Direct Ownership : 57 - Exercise of rights -6,101     22,522 22,522       Common Shares -6,101 22,522  
   
        3812364 2021-09-30 2021-10-04 Direct Ownership : 57 - Exercise of rights -6,101     16,421 16,421       Common Shares -6,101 16,421  
   
        3812368 2021-10-01 2021-10-04 Direct Ownership : 57 - Exercise of rights -8,134     8,287 8,287      
   
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities